Oral Contraceptive Pill Pharmacogenomics Study
This study aims to understand how your unique DNA affects how your body processes the hormones in oral contraceptive pills (birth control pills). Specifically, researchers are looking at how a common birth control pill, Desogestrel / Ethinyl Estradiol, is broken down in your body. They want to see if differences in your DNA can explain why these pills work differently for some people or cause different side effects. The study is open to women aged 18 to 45 who are in good general health. The main goal is to measure the levels of the hormones etonogestrel and ethinyl estradiol in your blood after taking the pill.
- Study design
- This is an interventional study planning to enroll 700 participants. It is not specified if it is randomized or blinded.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Hormone levels will be measured on Cycle 1, Day 22 (each cycle is 28 days).
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Oral Contraceptive Pill (OCP) Pharmacogenomics
At a glance
Conditions
Where it's being run
2 sites across 2 statesStudy leadership
- Aaron M Lazorwitz, MD, PhD · PRINCIPAL_INVESTIGATOR · Yale University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Serum etonogestrel concentrationMeasured as a trough concentration on Cycle 1, Day 22 (each cycle is 28 days)
Pharmacokinetic measurement for progestin
- Serum ethinyl estradiol concentrationMeasured as a trough concentration on Cycle 1, Day 22 (each cycle is 28 days)
Pharmacokinetic measurement for estrogen